查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1508417

中枢神经系统治疗市场 - 全球产业分析、规模、份额、成长、趋势和预测，2024-2034

Central Nervous System Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 174 Pages | 商品交期: 2-10个工作天内

价格

中枢神经系统 (CNS) 治疗市场 - 报告范围

TMR 关于全球中枢神经系统 (CNS) 治疗市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。 2034年全球中枢神经系统（CNS）治疗市场，以2024年为基准年，2034年为预测年。该报告也提供了2024年至2034年全球中枢神经系统（CNS）治疗市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解中枢神经系统 (CNS) 治疗市场。

市场概况
2023年市场价值 1024 亿美元
2034 年市场价值 2,318 亿美元
复合年增长率 7.7%

该报告深入研究了全球中枢神经系统（CNS）治疗市场的竞争格局。全球中枢神经系统 (CNS) 治疗市场的主要参与者已被确定，并且每一位参与者都已根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球中枢神经系统 (CNS) 治疗市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：市场

第 4 章：市场概述

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：依药物类别

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依药品类别，2020-2034
    • 止痛药
    • 抗胆碱能药物
    • 抗惊厥药
    • 镇静剂和催眠药
    • 抗忧郁药
    • 其他（抗精神病药物等）
  • 市场吸引力分析：依药品类别

第 7 章：全球市场分析与预测：按疾病类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依疾病类型，2020-2034
    • 神经退化性疾病
      • 阿兹海默氏症
      • 帕金森氏症
      • 亨丁顿舞蹈症
      • 肌萎缩侧索硬化症
      • 其他（多发性硬化症等）
    • 精神健康
      • 焦虑症
      • 癫痫
      • 精神障碍
      • 其他（情绪障碍等）
    • 神经血管疾病
    • 中枢神经系统创伤
    • 中枢神经系统癌症
    • 其他（传染病等）
  • 市场吸引力分析：按疾病类型

第 8 章：全球市场分析与预测：按配销通路

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按配销通路，2020-2034
    • 医院药房
    • 零售药局
    • 网路药局
  • 市场吸引力分析：按配销通路

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第15章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Biogen
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Merck & Co. Inc.
    • AstraZeneca
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Takeda Pharmaceuticals
    • Johnson & Johnson Services, Inc.
Product Code: TMRGL74787

Central Nervous System (CNS) Therapeutics Market - Scope of Report

TMR's report on the global central nervous system (CNS) therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global central nervous system (CNS) therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global central nervous system (CNS) therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the central nervous system (CNS) therapeutics market.

Market Snapshot
Market Value in 2023US$ 102.4 Bn
Market Value in 2034US$ 231.8 Bn
CAGR7.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global central nervous system (CNS) therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global central nervous system (CNS) therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global central nervous system (CNS) therapeutics market.

The report delves into the competitive landscape of the global central nervous system (CNS) therapeutics market. Key players operating in the global central nervous system (CNS) therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global central nervous system (CNS) therapeutics market profiled in this report.

Key Questions Answered in Global central nervous system (CNS) therapeutics Market Report:

  • What is the sales/revenue generated by central nervous system (CNS) therapeutics across all regions during the forecast period?
  • What are the opportunities in the global central nervous system (CNS) therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Central Nervous System (CNS) Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global central nervous system (CNS) therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global central nervous system (CNS) therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global central nervous system (CNS) therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Central Nervous System (CNS) Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Analgesics
    • 6.3.2. Anti-Cholinergic Agents
    • 6.3.3. Anticonvulsants
    • 6.3.4. Sedatives and Hypnotics
    • 6.3.5. Anti-Depressants
    • 6.3.6. Others (Antipsychotics, etc.)
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Disease Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Type, 2020-2034
    • 7.3.1. Neurodegenerative Disorders
      • 7.3.1.1. Alzheimer's Disease
      • 7.3.1.2. Parkinson's Disease
      • 7.3.1.3. Huntington's Disease
      • 7.3.1.4. Amyotrophic Lateral Sclerosis
      • 7.3.1.5. Others (Multiple Sclerosis, etc.)
    • 7.3.2. Mental Health
      • 7.3.2.1. Anxiety Disorders
      • 7.3.2.2. Epilepsy
      • 7.3.2.3. Psychotic Disorders
      • 7.3.2.4. Others (Mood Disorders, etc.)
    • 7.3.3. Neurovascular Diseases
    • 7.3.4. CNS Trauma
    • 7.3.5. CNS Cancer
    • 7.3.6. Others (Infectious Disorders, etc.)
  • 7.4. Market Attractiveness Analysis, by Disease Type

8. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Central Nervous System (CNS) Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Class, 2020-2034.
    • 10.3.1. Analgesics
    • 10.3.2. Anti-Cholinergic Agents
    • 10.3.3. Anticonvulsants
    • 10.3.4. Sedatives and Hypnotics
    • 10.3.5. Anti-Depressants
    • 10.3.6. Others (Antipsychotics, etc.)
  • 10.4. Market Value Forecast, by Disease Type, 2020-2034.
    • 10.4.1. Neurodegenerative Disorders
      • 10.4.1.1. Alzheimer's Disease
      • 10.4.1.2. Parkinson's Disease
      • 10.4.1.3. Huntington's Disease
      • 10.4.1.4. Amyotrophic Lateral Sclerosis
      • 10.4.1.5. Others (Multiple Sclerosis, etc.)
    • 10.4.2. Mental Health
      • 10.4.2.1. Anxiety Disorders
      • 10.4.2.2. Epilepsy
      • 10.4.2.3. Psychotic Disorders
      • 10.4.2.4. Others (Mood Disorders, etc.)
    • 10.4.3. Neurovascular Diseases
    • 10.4.4. CNS Trauma
    • 10.4.5. CNS Cancer
    • 10.4.6. Others (Infectious Disorders, etc.)
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034.
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Class
    • 10.7.2. By Disease Type
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Central Nervous System (CNS) Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Class, 2020-2034
    • 11.3.1. Analgesics
    • 11.3.2. Anti-Cholinergic Agents
    • 11.3.3. Anticonvulsants
    • 11.3.4. Sedatives and Hypnotics
    • 11.3.5. Anti-Depressants
    • 11.3.6. Others (Antipsychotics, etc.)
  • 11.4. Market Value Forecast, by Disease Type, 2020-2034.
    • 11.4.1. Neurodegenerative Disorders
      • 11.4.1.1. Alzheimer's Disease
      • 11.4.1.2. Parkinson's Disease
      • 11.4.1.3. Huntington's Disease
      • 11.4.1.4. Amyotrophic Lateral Sclerosis
      • 11.4.1.5. Others (Multiple Sclerosis, etc.)
    • 11.4.2. Mental Health
      • 11.4.2.1. Anxiety Disorders
      • 11.4.2.2. Epilepsy
      • 11.4.2.3. Psychotic Disorders
      • 11.4.2.4. Others (Mood Disorders, etc.)
    • 11.4.3. Neurovascular Diseases
    • 11.4.4. CNS Trauma
    • 11.4.5. CNS Cancer
    • 11.4.6. Others (Infectious Disorders, etc.)
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034.
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Distribution Channel, 2020-2034.
    • 11.6.1. Hospitals
    • 11.6.2. Biopharmaceutical Companies
    • 11.6.3. Research Organizations and Academic Institutes
  • 11.7. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.7.1. Germany
    • 11.7.2. U.K.
    • 11.7.3. France
    • 11.7.4. Italy
    • 11.7.5. Spain
    • 11.7.6. Rest of Europe
  • 11.8. Market Attractiveness Analysis
    • 11.8.1. By Drug Class
    • 11.8.2. By Disease Type
    • 11.8.3. By Distribution Channel
    • 11.8.4. By Country/Sub-region

12. Asia Pacific Central Nervous System (CNS) Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Class, 2020-2034.
    • 12.3.1. Analgesics
    • 12.3.2. Anti-Cholinergic Agents
    • 12.3.3. Anticonvulsants
    • 12.3.4. Sedatives and Hypnotics
    • 12.3.5. Anti-Depressants
    • 12.3.6. Others (Antipsychotics, etc.)
  • 12.4. Market Value Forecast, by Disease Type, 2020-2034.
    • 12.4.1. Neurodegenerative Disorders
      • 12.4.1.1. Alzheimer's Disease
      • 12.4.1.2. Parkinson's Disease
      • 12.4.1.3. Huntington's Disease
      • 12.4.1.4. Amyotrophic Lateral Sclerosis
      • 12.4.1.5. Others (Multiple Sclerosis, etc.)
    • 12.4.2. Mental Health
      • 12.4.2.1. Anxiety Disorders
      • 12.4.2.2. Epilepsy
      • 12.4.2.3. Psychotic Disorders
      • 12.4.2.4. Others (Mood Disorders, etc.)
    • 12.4.3. Neurovascular Diseases
    • 12.4.4. CNS Trauma
    • 12.4.5. CNS Cancer
    • 12.4.6. Others (Infectious Disorders, etc.)
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034.
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Distribution Channel, 2020-2034.
    • 12.6.1. Hospitals
    • 12.6.2. Biopharmaceutical Companies
    • 12.6.3. Research Organizations and Academic Institutes
  • 12.7. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.7.1. China
    • 12.7.2. Japan
    • 12.7.3. India
    • 12.7.4. Australia & New Zealand
    • 12.7.5. Rest of Asia Pacific
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Drug Class
    • 12.8.2. By Disease Type
    • 12.8.3. By Distribution Channel
    • 12.8.4. By Country/Sub-region

13. Latin America Central Nervous System (CNS) Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Class, 2020-2034
    • 13.3.1. Analgesics
    • 13.3.2. Anti-Cholinergic Agents
    • 13.3.3. Anticonvulsants
    • 13.3.4. Sedatives and Hypnotics
    • 13.3.5. Anti-Depressants
    • 13.3.6. Others (Antipsychotics, etc.)
  • 13.4. Market Value Forecast, by Disease Type, 2020-2034.
    • 13.4.1. Neurodegenerative Disorders
      • 13.4.1.1. Alzheimer's Disease
      • 13.4.1.2. Parkinson's Disease
      • 13.4.1.3. Huntington's Disease
      • 13.4.1.4. Amyotrophic Lateral Sclerosis
      • 13.4.1.5. Others (Multiple Sclerosis, etc.)
    • 13.4.2. Mental Health
      • 13.4.2.1. Anxiety Disorders
      • 13.4.2.2. Epilepsy
      • 13.4.2.3. Psychotic Disorders
      • 13.4.2.4. Others (Mood Disorders, etc.)
    • 13.4.3. Neurovascular Diseases
    • 13.4.4. CNS Trauma
    • 13.4.5. CNS Cancer
    • 13.4.6. Others (Infectious Disorders, etc.)
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034.
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Distribution Channel, 2020-2034.
    • 13.6.1. Hospitals
    • 13.6.2. Biopharmaceutical Companies
    • 13.6.3. Research Organizations and Academic Institutes
  • 13.7. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.7.1. Brazil
    • 13.7.2. Mexico
    • 13.7.3. Rest of Latin America
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Drug Class
    • 13.8.2. By Disease Type
    • 13.8.3. By Distribution Channel
    • 13.8.4. By Country/Sub-region

14. Middle East & Africa Central Nervous System (CNS) Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Class, 2020-2034
    • 14.3.1. Analgesics
    • 14.3.2. Anti-Cholinergic Agents
    • 14.3.3. Anticonvulsants
    • 14.3.4. Sedatives and Hypnotics
    • 14.3.5. Anti-Depressants
    • 14.3.6. Others (Antipsychotics, etc.)
  • 14.4. Market Value Forecast, by Disease Type, 2020-2034.
    • 14.4.1. Neurodegenerative Disorders
      • 14.4.1.1. Alzheimer's Disease
      • 14.4.1.2. Parkinson's Disease
      • 14.4.1.3. Huntington's Disease
      • 14.4.1.4. Amyotrophic Lateral Sclerosis
      • 14.4.1.5. Others (Multiple Sclerosis, etc.)
    • 14.4.2. Mental Health
      • 14.4.2.1. Anxiety Disorders
      • 14.4.2.2. Epilepsy
      • 14.4.2.3. Psychotic Disorders
      • 14.4.2.4. Others (Mood Disorders, etc.)
    • 14.4.3. Neurovascular Diseases
    • 14.4.4. CNS Trauma
    • 14.4.5. CNS Cancer
    • 14.4.6. Others (Infectious Disorders, etc.)
  • 14.5. Market Value Forecast, by Distribution Channel, 2020-2034.
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Distribution Channel, 2020-2034.
    • 14.6.1. Hospitals
    • 14.6.2. Biopharmaceutical Companies
    • 14.6.3. Research Organizations and Academic Institutes
  • 14.7. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.7.1. GCC Countries
    • 14.7.2. South Africa
    • 14.7.3. Rest of Middle East & Africa
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Drug Class
    • 14.8.2. By Disease Type
    • 14.8.3. By Distribution Channel
    • 14.8.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Biogen
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Otsuka Pharmaceutical Co., Ltd.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Eli Lilly and Company
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Merck & Co. Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. AstraZeneca
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Novartis AG
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Teva Pharmaceutical Industries Ltd.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Pfizer Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Takeda Pharmaceuticals
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Johnson & Johnson Services, Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 03: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 05: North America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 06: North America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 07: North America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 08: North America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 09: Europe Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 11: Europe Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 12: Europe Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Asia Pacific Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 15: Asia Pacific Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 16: Asia Pacific Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Latin America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 19: Latin America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 20: Latin America Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2020-2034
  • Table 23: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 24: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) and Distribution (%), by Region, 2023. and 2034
  • Figure 02: Global Central Nervous System (CNS) Therapeutics Market Revenue (US$ Bn), by Drug Class, 2023
  • Figure 03: Global Central Nervous System (CNS) Therapeutics Market Value Share, by Drug Class, 2023
  • Figure 04: Global Central Nervous System (CNS) Therapeutics Market Revenue (US$ Bn), by Disease Type, 2023
  • Figure 05: Global Central Nervous System (CNS) Therapeutics Market Value Share, by Disease Type, 2023
  • Figure 06: Global Central Nervous System (CNS) Therapeutics Market Revenue (US$ Bn), by Distribution Channel, 2023
  • Figure 07: Global Central Nervous System (CNS) Therapeutics Market Value Share, by Distribution Channel, 2023
  • Figure 08: Global Central Nervous System (CNS) Therapeutics Market Value Share, by Region, 2023
  • Figure 09: Global Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 10: Global Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
  • Figure 11: Global Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
  • Figure 13: Global Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 14: Global Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
  • Figure 15: Global Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Region, 2023. and 2034
  • Figure 17: Global Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country, 2023. and 2034
  • Figure 21: North America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
  • Figure 22: North America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
  • Figure 23: North America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
  • Figure 24: North America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 26: North America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Europe Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023. and 2034
  • Figure 30: Europe Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
  • Figure 31: Europe Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
  • Figure 32: Europe Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
  • Figure 33: Europe Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 35: Europe Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023. and 2034
  • Figure 39: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
  • Figure 40: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
  • Figure 41: Asia Pacific Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
  • Figure 42: Asia Pacific Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 44: Asia Pacific Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Latin America Central Nervous System (CNS) Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023. and 2034
  • Figure 48: Latin America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
  • Figure 49: Latin America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
  • Figure 50: Latin America Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
  • Figure 51: Latin America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 53: Latin America Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 54: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023. and 2034
  • Figure 57: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Drug Class, 2023. and 2034
  • Figure 58: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Disease Type, 2023. and 2034
  • Figure 59: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Value Share Analysis, by Distribution Channel, 2023. and 2034
  • Figure 60: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 62: Middle East & Africa Central Nervous System (CNS) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034